Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
5.72
-0.26 (-4.35%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.65 - 6.02
52 week 5.55 - 16.98
Open 5.93
Vol / Avg. 0.00/831,576.00
Mkt cap 269.36M
P/E     -
Div/yield     -
EPS -2.64
Shares 49.23M
Beta 1.58
Inst. own 111%
Feb 22, 2016
Q4 2015 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 13, 2016
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2016
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 46.88% -10.56%
Operating margin 47.67% -4.80%
EBITD margin - -3.73%
Return on average assets 59.45% -5.81%
Return on average equity 151.44% -8.48%
Employees 195 -
CDP Score - -

Address

784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 60
Bio & Compensation  - Reuters
William C. Bertrand Jr. Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Sujay Kango Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters